Today’s Market Runner: What Next for Concordia International Corp Stock After Today’s Significant Increase?

Today's Market Runner: What Next for Concordia International Corp Stock After Today's Significant Increase?

The stock of Concordia International Corp (NASDAQ:CXRX) is a huge mover today! About 1.55 million shares traded hands. Concordia International Corp (NASDAQ:CXRX) has declined 92.52% since April 8, 2016 and is downtrending. It has underperformed by 98.17% the S&P500.
The move comes after 9 months positive chart setup for the $101.52M company. It was reported on Nov, 10 by Barchart.com. We have $3.37 PT which if reached, will make NASDAQ:CXRX worth $53.81M more.

Concordia International Corp (NASDAQ:CXRX) Ratings Coverage

Out of 9 analysts covering Concordia Healthcare Corp. (NASDAQ:CXRX), 5 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 56% are positive. Concordia Healthcare Corp. has been the topic of 18 analyst reports since August 11, 2015 according to StockzIntelligence Inc. As per Thursday, October 1, the company rating was reinitiated by RBC Capital Markets. The stock of Concordia International Corp (NASDAQ:CXRX) has “Underperformer” rating given on Monday, August 15 by IBC. The rating was downgraded by GMP Securities to “Hold” on Monday, August 15. As per Monday, September 19, the company rating was upgraded by Scotia Capital. The firm has “Neutral” rating given on Monday, June 6 by Goldman Sachs. Laurentian maintained the stock with “Buy” rating in Tuesday, March 29 report. Scotia Capital maintained the shares of CXRX in a report on Tuesday, September 29 with “Sector Outperform” rating. The stock has “Sector Outperform” rating given by Scotia Capital on Friday, October 16. The rating was initiated by IBC with “Sector Perform” on Monday, November 30. The firm has “Neutral” rating given on Monday, August 15 by Goldman Sachs.

According to Zacks Investment Research, “Concordia International Corp is a diverse pharmaceutical company which focused on legacy pharmaceutical products and orphan drugs. The company also markets orphan drugs through its Orphan Drug Division, currently consisting of Photofrin(R) for the treatment of certain rare forms of cancer, which is currently undergoing testing for potential new indications. Concordia International Corp, formerly known as Concordia Healthcare Corp, is headquartered in Oakville, Canada.”

More notable recent Concordia International Corp (NASDAQ:CXRX) news were published by: Prnewswire.com which released: “Concordia International Corp. Announces Communication With CMA” on October 25, 2016, also Prnewswire.com with their article: “Concordia International Corp. Announces CEO Transition Plan” published on October 21, 2016, Marketwatch.com published: “Concordia International Corp. Announces Second Cross Currency Swap Agreement” on November 01, 2016. More interesting news about Concordia International Corp (NASDAQ:CXRX) were released by: Business.Financialpost.com and their article: “Concordia International Corp. faces much more downside – CIBC” published on October 14, 2016 as well as Nasdaq.com‘s news article titled: “Mid-Day Market Update: Dow Gains Over 300 Points; Concordia International …” with publication date: November 07, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment